Selective cyclooxygenase 2 inhibitors for the treatment of rheumatological manifestations of inflammatory bowel disease
Published Online: 15 APR 2009
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
How to Cite
Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY. Selective cyclooxygenase 2 inhibitors for the treatment of rheumatological manifestations of inflammatory bowel disease (Protocol). Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD007744. DOI: 10.1002/14651858.CD007744.
- Publication Status: New
- Published Online: 15 APR 2009
This is the protocol for a review and there is no abstract. The objectives are as follows:
The objective of this study is to evaluate the tolerability of COX-2 inhibitors (celecoxib, rofecoxib, valdecoxib, etoricoxib, and lumiracoxib) for the treatment the rheumatological manifestations of IBD and to identify gaps in knowledge that will suggest the most fruitful direction for future research.